Synbody Biotechnology
Farmington
About Synbody Biotechnology
Synbody Biotechnology (SBI) is a start-up biotechnology company based on a powerful synthetic antibody, or "Synbody," technology recently discovered at Arizona State University. Synbodies revolutionize the field of high affinity, high specificity therapeutic agents by creating antibody-like function from small purely synthetic peptides. It is SBI's mission to leverage the Synbody technology to create a pipeline of superior human therapeutics across multiple therapeutic areas. SBI seeks to realize the opportunity for synbodies as human therapeutics through a combined strategy comprising corporate partnerships, out-licensing agreements and in-house development.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $750.0K
- Funding stage: Seed
- Last round: Seed (Mar 2012)
- Website: synbodybio.com
- Phone: 484-883-9725
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/synbody-biotechnology-2102706 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.